Microsoft word - cv-michalski.doc

Michael H. Michalski, M.D.
A Medical Corporation
Home: 4286 Corte Langostino Office: 8851 Center Drive Tax ID: 20-0147011 San Diego, CA 92130 Suite 610 (858) 350-9693 La Mesa, CA 91942 [email protected] (619) 667-7072 cell ( 619) 733-6882 (619) 667-7064 fax Fellowship: Cardiovascular Disease Naval Medical Center, San Diego, CA July 1996 - July 1999 Interventional Cardiology training Scripps Clinic, La Jolla, CA Program Director: Dr. Paul Teirstein July 1998 – Feb 1999 Residency/Internship: Internal Medicine Naval Medical Center, San Diego, CA June 1992 – July 1995 Medical School: M.D. Georgetown University School of Medicine, Washington, DC August 1988 – May 1992 Undergraduate: B.S. (Chemistry) Rockhurst College, Kansas City, MO August 1984 – May 1988 Solo practice (Michael H. Michalski, M.D., A Medical Corporation) • General, Invasive, and Interventional Cardiology • Lifetime experience of >6,000 cardiac catheterizations and • Peripheral vascular angiography and intervention • Renal, Iliac, Femoral, and Subclavian disease • >500 diagnostic and >250 interventional procedures La Mesa Cardiac Center, La Mesa, CA (July 2002-Nov.2003) • General, Invasive, and Interventional Cardiology Naval Medical Center, San Diego, CA (June 2001 – July 2002). • Director, Cardiac Catheterization Laboratory
• General and Interventional Cardiology
• Clinical staff: Cardiology Fellowship Program
Naval Hospital, Camp Pendleton, Oceanside, CA (June 1999 – June 2001) • Head, Cardiology Division • Director, Intensive Care Unit Naval Medical Center, San Diego, CA (July 1995 – June 1996) 1995-1996 Chief Medical Resident (Naval Medical Center, San Diego) 1999-2001 Medical Director, ICU (Camp Pendleton Hospital, CA) 2001-2002 Director, Cardiac Cath Lab (Naval Medical Center, San Diego) 2003-2005 Member, Endovascular Supervisory Cmte (Grossmont Hospital) 2005-2007 Member, Quality Committee (Alvarado Hospital) 2007-pres Member, Endovascular Supervisory Cmte (Alvarado Hospital) 2008-2009 Member, Cardiovascular Supervisory Sub-Cmte (Alvarado) 2009-pres Member, Medicine Supervisory Committee (Alvarado Hospital) 2010-pres Chairman, Cardiovascular Supervisory Sub-Cmte (Alvarado) 2010-pres Member-at-large, Medical Executive Committee (Alvarado) • NIH-funded, multicenter trial with over 42,000 patients comparing four medical treatment strategies for patients with hypertension. • Pfizer-funded, multicenter trial comparing high and low dose Lipitor for secondary prevention of coronary heart disease • NIH-funded, multicenter trial comparing anticoagulation and rate control versus anti-arrhythmic therapy in patients with atrial Fellowship Research: “Effect of Aorto-Coronary Bypass Graft Markers on Saphenous Vein Graft Patency, A Prospective Trial; Naval Medical Center, San Diego, CA PUBLICATIONS McCurley J.M., Michalski M.H., et al., “Furosemide and the Progression of Left Ventricular Dysfunction in Experimental Heart Failure.” J Am Coll Cardiol. 2004 Sep 15; 44(6):1301-7. * Cardiovascular Diseases, American Board of Internal Med, issued 11/99 CERTIFICATION (pending renewal: recertification exam passed 2009) * Interventional Cardiology, American Board of Internal Med, issued 11/00 Diplomate, National Board of Medical Examiners, 7/93 Medical License, State of California, Lic # G86189 X-ray/Fluoroscopy Supervisor and Operator License PROFESSIONAL California Medical Association MEMBERSHIPS San Diego County Medical Society Speakers Bureau: Sanofi-Aventis, Bristol-Myers-Squibb and Pfizer


Geographic patterns of genetic variation in brushtail possums trichosurus vulpecula and implications for pest control

1 School of Biological Sciences, Victoria University, P.O. Box 600, Wellington. Present address: Science Directorate, Department of Conservation, P.O. Box 10420, Wellington. 2 Forest Research Institute, P.O. Box 31-011, Christchurch. Present address: Advocacy and Extension Directorate, Department of Conservation, P.O. Box 10420, Wellington. GEOGRAPHIC PATTERNS OF GENETIC VARIATION INBRUSHTAIL

Breaking the obesity barrier -- pdf.pdf Breaking the Obesity Barrier: Near-Term Prospects for Breakthrough Treatments Dec. 22, 2005 -- The prevalence of overweight and obesity is increasing at an alarming rate, not only in the United States but worldwide. The World Health Organization recently warned that the number of overweight and obese people worldwide could reach 1.5 billion by 2015. ( Red Herring ,

Copyright © 2009-2018 Drugs Today